Med-Tech Innovation editor Ian Bolland speaks to Lionel Maritan, associate director – research and development Becton Dickinson (BD), about the company’s Intevia 2.25ml autoinjector which is set to launch at the end of 2021 or the start of 2022.
Andreas Meliniotis, director of Device Development at Vectura explains how connected devices are helping patients better manage their medications and improve adherence.
Med-Tech Innovation editor Ian Bolland speaks to life sciences supplier Abcam about the company’s latest efforts to develop a new cell delivery solution that can potentially improve the therapeutic viability of molecules.
EPM speaks to Kevin Deane, vice president of Front-End Innovation and Connected Health at. Phillips-Medisize about the promise of connected health in drug delivery for patients, pharmaceutical providers, and the healthcare industry.
Anil Kumar Busimi - senior global product manager for SCHOTT iQ Platform at SCHOTT, explores how innovation in packaging is giving patients more options to administer medication from home.
Lu Rahman speaks to George I’ons, head of product strategy and insights at Owen Mumford Pharmaceutical Services about the near-term competitive biosimilars market in the USA and Europe, and its impact on drug delivery device design.
EPM speaks to Nigel Theobald, CEO of N4 Pharma who discusses the formulation challenges that can occur during drug development and what the company is doing to improve vaccine delivery systems.
Craig Scherer - marketing director for the Insight Innovation Center at Nemera discusses how the company’s extended capabilities in front-end innovation bring new advantages for pharma customers.
With the emergence of CBD-based medicines, Sarath Chandar, chief scientific officer, SPI Pharma guides readers through the bioavailability challenges facing this sector of the industry.
Kevin Deane, vice-president, Innovation at Phillips-Medisize examines the relationship between health, pharmaceutical companies and drug delivery device developers.
At the confluence of Moore’s law and Metcalfe’s law the next frontier in drug delivery becomes data-driven, personalised and outcome-based- Dr Ramin Rafiei, director of digital healthcare at SHL Group writes.
